Welcome To Europe
This article was originally published in RPM Report
The comments by US-based and European-based senior executives about the impact of health care reform varied markedly. By and large, European companies said they anticipated the impact and would not change guidance as a result; US companies highlighted adjustments to revenues and earnings forecast-and promised or hinted at cuts to make it up. Here is a sampling of the comments, from both sides of the Atlantic.
You may also be interested in...
Merck wasn’t as quick to the COVID vaccine race as some others, but it believed that its use of ‘proven platforms’ would win out in the end. Not anymore.
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.